Slayton R E, Blessing J A, Clarke-Pearson D
Department of Medicine, Rush-Presbyterian St. Luke's Medical Center, Chicago, IL.
Invest New Drugs. 1991 Feb;9(1):93-4. doi: 10.1007/BF00194555.
AZQ was given intravenously to 23 patients with mixed mesodermal sarcoma of the uterus refractory to conventional treatment at a dose of 22.5-30 mg/m2 q three weeks. There was one partial response lasting seven weeks and one drug-related death. Based upon the activity observed in this trial, there does not appear to be a significant role for AZQ as a salvage agent for mixed mesodermal sarcomas of the uterus at the dose and schedule tested.
对23例传统治疗无效的子宫混合性中胚层肉瘤患者静脉注射AZQ，剂量为22.5 - 30mg/m²，每三周一次。有1例部分缓解持续7周，1例与药物相关的死亡。基于该试验观察到的活性，在所测试的剂量和给药方案下，AZQ作为子宫混合性中胚层肉瘤的挽救治疗药物似乎没有显著作用。
